n the past decade, cardiologists have witnessed a revolution in the knowledge of the electrophysiological basis and mechanisms of (rare) arrhythmias. This development relates, in particular, to the identification of the molecular basis of several hereditary arrhythmia syndromes, which has greatly improved the care of affected patients and their families. For gene carriers, who are often not (yet) symptomatic, timely and tailored treatment, both pharmacological and through personalized lifestyle advice, has come within reach. At the same time, and of equal importance, unaffected family members (non-carriers) can be reassured.
The inherited arrhythmia syndromes may be subdivided into the primary arrhythmia syndromes, in which the arrhythmogenic substrate is found in the electrical properties of the heart, and the secondary arrhythmia syndromes. In the latter, the heart is structurally altered by hypertrophy, dilatation or fatty and/or fibrotic infiltration. The cardiomyopathies are the most important disease entities in this group.
The primary arrhythmia syndromes are the topic of this brief review. Their number continues to grow, mainly as a result of the above described development and the associated growing interest in rare ECGs. In the 1990s, the long QT syndrome (LQTS), regarded as 1 disease entity for more than 30 years, was subdivided into various forms, on the basis of the molecular genetic aberrancy. In the same era, Brugada syndrome (BS) was described. More recently, the short QT syndrome (SQTS) was recognized and subdivided into various categories. BS is now also subdivided into several genetic subtypes. Overlap in clinical and electrocardiographic properties between the various apparently distinct entities has been reported. Even the previously defined strict distinction between structural heart disease and "ion channelopathies" has become more and more vague because of the identification of subclinical structural changes in patients with a primary electrical disease. This review will briefly discuss the various inherited arrhythmia syndromes and aims to make the reader more familiar with these exciting, though rare, clinical entities.
Long QT-Interval Syndromes
The familial nature of LQTS was recognized from the very beginning. In the first report, an autosomal recessive disease associated with congenital deafness was described ('the Jervell and Lange-Nielsen syndrome', JLN). 1 A few years later, an autosomal dominant variant with only QT prolongation was reported ('Romano-Ward syndrome'). 2, 3 Indeed, QT prolongation (actually QTc prolongation, ie, the QT interval corrected for heart rate) is the ECG signature of the disease and is associated with an enhanced risk of malignant ventricular tachyarrhythmias that lead to symptoms ranging from short-lasting syncope to sudden cardiac death (SCD). The Romano-Ward syndrome is far more common than the JLN syndrome. The former affects individuals in a wide age range, including young children, whereas the JLN variant affects mainly children.
In the mid 1990s, the original subdivision into RomanoWard syndrome and JLN syndrome was replaced by a subdivision based on the molecular genetic cause. Since then, LQTS has been subdivided into 10 subtypes and JLN syndrome into 2 subtypes (Table 1 ). 4 The majority of genes involved encode subunits of ion channels. The remaining genes encode proteins that affect ion channel expression. The affected ion channels are either expressed in the sarcolemmal membrane in lower numbers than expected, or do not function properly. In LQTS types 1, 2, 5, 6 and 7, variants in potassium channel genes (KCNQ1, KCNH2, KCNE1, KCNE2, and KCNJ2, respectively) are involved (for review, see Wilde and Bezzina 4 ). The common denominator of the various causal genetic aberrancies in these channels is a loss of function. Less potassium outward cur- rent during the plateau phase of the action potential delays repolarization, thereby prolonging the action potential and the QTc interval. LQTS 3 and 8 involve the cardiac sodium and calcium channels, respectively. In these subtypes, the causes are gain-of-function mutations, which lead to increased inward current during the action potential plateau phase and, consequently, prolongation of the QTc interval. LQTS 10 relates to a subunit of the cardiac sodium channel (SCN4b), whereas LQTS 4 and 9 are based on variations in the proteins ankyrin and caveolin, which are involved in ion channel trafficking and localization, respectively. [5] [6] [7] It is important to realize that the putative causality of the genetic findings is not based on sound linkage data in all subtypes. In particular, single individuals or small families with just a few affected individuals form the basis of the suggested causal relationship in LQTS 5, 6, 9, and 10. The current subdivision is not unimportant, because there appears to be a strong genotype -phenotype relationship. Shortly after the identification of heterogeneity in LQTS, gene-specific T-wave morphologies were described for the 3 most common subtypes, which account for 85% of the genotyped population 8 (ie, LQTS 1, 2, and 3). In the years that followed, these observations were extended. 9 Moreover, gene-specific clinical parameters were also identified. 10 In particular, the triggers for symptoms received a lot of attention. Indeed, highly gene-specific triggers are present for LQTS 1 (swimming and diving) and LQTS 2 (auditory stimuli). [11] [12] [13] [14] In addition, exercise-or stressrelated arrhythmias are frequently observed in LQTS 1 and 2, whereas the majority of events in LQTS 3 occur at rest. 14 Based on these observations, it is evident why anti-adrenergic interventions, in particular, -adrenoceptor blockade, are typically effective in LQTS 1 and 2, but less so in LQTS 3. 14,15 Based on the biophysical consequences of altered sodium current in LQTS 3, it has been speculated that sodium-channel blockers may be beneficial. 16 Indeed, a very significant reduction in QTc-interval during sodiumchannel blocker treatment has been shown. However, it should be stressed that, at present, long-term follow-up of patients on this drug class is lacking. At the same time, failure of such therapy has been reported. 17 Implantation of a pacemaker or an implantable cardioverter-defibrillator (ICD) is occasionally required in all 3 subtypes, maybe more so in LQTS 3 patients. Data on the other subtypes are scarce, although it is generally recognized that, in particular, LQTS 8 may be a highly malignant subtype.
The age of onset of symptoms is another clinical variable that displays some gene-specific features. 18 In LQTS 1, the age of onset is between 5 and 15 years in most, but is typically at puberty in LQTS 2 and 3 (in LQTS 3, it is somewhat later than in LQTS 2). 18 These observations may affect the decision about when to start treatment. In particular, in asymptomatic LQTS 3 patients, it may be beneficial to delay the onset of treatment (which may involve ICD implantation). However, prospective studies are lacking, so in general practice prophylactic treatment is usually started immediately after the diagnosis is made.
Other gene-specific features relate to extracardiac features in LQTS 7 and 8. 19, 20 In LQTS 7 ('Andersen syndrome'), these include episodic paraplegia, and facial and skeletal deformities. In LQTS 8 ('Timothy syndrome'), syndactyly, congenital heart defects, and autism are found. 19, 20 In LQTS 4, atrial arrhythmias and sinus node dysfunction are part of the phenotype. 6, 21 Finally, we recently described that the type of arrhythmia onset may also be gene-specific. That is to say, the hallmark tachyarrhythmia of LQTS, torsade de pointes ventricular tachycardia (VT), is most often tachycardia-dependent in LQTS 1 (Fig 1A) , whereas in LQTS 2, it is almost always preceded by a pause, which gives rise to the typical shortlong -short initiating sequence of RR intervals (Fig 1B) . 22 Whether these gene-dependent characteristics reflect genedependent arrhythmogenic mechanisms remains to be determined.
Short QT-Interval Syndrome
SQTS may be regarded as the mirror image of LQTS. Indeed, gain-of-function mutations in 3 LQTS-associated potassium-channel encoding genes have so far been found to cause SQTS. SQTS is a rare disease characterized by short QT-intervals on the ECG, short refractory periods throughout the heart, and a high arrhythmogenic potential (atrial and ventricular arrhythmias). [23] [24] [25] Disease onset seems to be at a young age in the few families/individuals that have been described so far. The gain-of-function mutations cause an increased outward current during the plateau phase of the action potential with concurrent abbreviation of the action potential and the QTc interval.
Because the number of reported patients is still so small, information on possible gene-specific clinical properties and/or therapy is lacking. Quinidine has been shown to normalize (ie, lengthen) the QTc intervals in individuals with a KCNH2 mutation (SQTS 1). 26 Sotalol was ineffective, probably because the familial mutation in the reported family resided in the sotalol-binding domain. 26 Hence, the lack of effect may be family-specific. In general, ICD therapy is currently considered the only effective treatment. 27 
Brugada Syndrome
BS was first described in 1992 by Pedro and Josep Brugada as a clinical entity consisting of right bundle branch block, right precordial ST segment elevation and SCD. 28 In recent years, it is increasingly recognized as a familial arrhythmia syndrome, particularly prevalent in South-East Asia and Japan, with a presumably high prevalence of SCD. The ECG signature of the syndrome is the right precordial ST segment elevation. Right bundle branch block may be present, but is not mandatory. Instead, conduction delay can be present at different cardiac levels, evidenced by prolonged PR intervals, abnormal electrical axis and, frequently, right ventricular conduction delay. BS patients are not often symptomatic (presyncope and syncope). On the other hand, SCD is, unfortunately, not infrequently the first manifestation. SCD may also be present in family members.
The diagnosis is based on the presence of the above described ECG signature, either spontaneously or after drug infusion, and 1 or more clinical parameters, 29, 30 which include documented ventricular fibrillation (VF), self-terminating polymorphic VT, a family history of SCD (<45 years of age), coved-type ST segment elevations in family members, inducibility of ventricular tachyarrhythmias during electrophysiological study (EPS), syncope or nocturnal agonal respiration. In the absence of one of these factors, the ECG is referred to as Brugada pattern. 29, 30 There should be no other factor(s) that can account for the ECG abnormality.
In the absence of typical ECG changes at baseline, the precordial leads may be placed in higher intercostal spaces (3 rd and, sometimes, 2 nd ), and several drugs may be used to unmask the required ECG pattern. [31] [32] [33] [34] These include class I antiarrhythmic drugs such as flecainide, ajmaline and procainamide, and, in Japan, pilsicainide. Ajmaline seems to be the drug with the best specificity/sensitivity. 35 The pathophysiological basis of the ECG changes is heavily discussed. The main theory revolves around the postulated heterogeneity in action potential morphology across the (right) ventricular wall (for review see Antzelevitch 36 ). In the presence of an abbreviated action potential in the epicardial layer and an unaffected action potential in the endocardial and mid-mural layers, electrotonic current will flow from endocardium to epicardium during the plateau phase. This will generate ST segment elevation in the electrodes that overlie this area. The differences in action potential morphology are most prominent in the right ventricular outflow tract, because the expression of relevant ion channels (the transient outward potassium current, Ito, in particular) differs between these regions, with the Ito channel being functionally most prevalent in the right ventricular outflow tract myocardium. 36 An alternative theory considers right ventricular conduction delay as critically important. 37 Long conduction delays are, however, needed to explain the right precordial conduction delay. For both theoretical explanations, clinical evidence has been provided over the years, but neither theory has been proven beyond doubt. 37 In the end, a combination of both theories may turn out to be pertinent. Of particular relevance in this discussion is the recent evidence that some BS patients have subclinical structural cardiac abnormalities, which may escape routine clinical imaging modalities and only become evident with microscopy. In fact, all studied pathoanatomical samples of deceased BS patients to date harbor structural abnormalities to some extent. 38, 39 At present, 2 genes have been identified that have a sound causal relationship. The first is the cardiac sodium-channel encoding gene SCN5a. 40 It is important to note that genetic linkage data to prove causality of SCN5a mutations do not exist, with the exception of data on a very large family with a combined phenotype of BS and LQT 3. 41 On the other hand, numerous individuals and small families with BS and a SCN5a mutation have been described. All mutations harbor a loss of function effect (ie, less sodium inward current during the upstroke (phase 0) of the action potential). 40 In the transmural heterogeneity theory, it is assumed that a loss of the plateau phase may ensue if reduced inward current is present to oppose a given amount of Ito. In the delayed conduction theory, reduced inward sodium current directly translates into reduced conduction velocity. The second gene was very recently identified in a family in which the gene defect was previously linked to a locus on chromosome 3, next to SCN5a. 42 The gene product, GPD1L, seems to affect sodium channel function, leading to a decrease in current amplitude with similar consequences as described above. 43 Very recently, 2 other genes, which both affect the amplitude of the calcium current, have been identified in individual patients. Biophysical data reveal a reduction in the calcium inward current which will also affect the duration of the action potential plateau phase. 44 Another issue that is heavily discussed is the appropriate treatment of BS patients. Whereas there is consensus that symptomatic BS patients (including those who have been resuscitated) should receive an ICD, there is controversy on how to manage asymptomatic patients with a spontaneous type 1 ECG (coved-type ECG). Reported cardiac death risks vary among different studies, ranging from 1-2% to 14% at approximately 3 years of follow-up. [45] [46] [47] Some authors use an EPS for risk stratification. According to these investigators, inducible patients are considered at high risk and are treated with an ICD, whereas non-inducible patients are considered safe and receive careful follow-up. 45 However, others do not consider the EPS outcome as a parameter with sufficient predictive power and consider asymptomatic patients at low risk, based on relatively long-term follow-up data. 46, 47 A recent meta-analysis appeared to support the latter approach by showing that the EPS is not sufficiently predictive. 48 In general, patients should be advised to refrain from using drugs that may elicit a type 1 ECG, and to seek medical attention in the case of fever. 29, 30 Hyperthermia has been shown to elicit a type 1 ECG and is not infrequently associated with malignant arrhythmias.
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
CPVT is an inherited arrhythmia disorder characterized by polymorphic VT or VF that is elicited by increased adrenergic tone. This syndrome was first described by the late Philippe Coumel and associates in the 1970s and more extensively in a seminal paper in 1995. 49 Physical and/or emotional stress are the typical symptom triggers. Often, the disease presents in young children, and the family history is frequently characterized by premature SCD, which is associated with the above-mentioned, typical, triggers. When left untreated, the risk of SCD is quite high. 50 The diagnosis is easily made by an exercise test or 24-h Holter monitoring. At baseline, bradycardia is usually observed. 51 During exercise, isolated ventricular extrasystoles appear at a patient-specific heart rate. With ongoing exercise, the arrhythmias become more complex (ie, bigeminy, bidirectional VT and, occasionally, VF). 49 Similar observations can be made on Holter recordings where, in particular, the relationship between the occurrence of arrhythmias and the heart rate should be studied.
Based on the causal genes involved, it appears that impaired cellular calcium homeostasis is central in this disorder. In the early years of this century, the human ryanodine receptor gene (hRyR2) and the calsequestrin gene (CASQ2), both key players in the calcium homeostasis of myocardial cells, were unmasked as causal genes for this disorder. [52] [53] [54] The first gene was identified in various small families with many de novo mutations, and in a large Finnish family with autosomal dominant inheritance. 52, 53 A CASQ2 mutation was found in a large Bedouin family as an autosomal recessive trait. 54 Calcium overload secondary to malfunctioning gene products underlies the arrhythmias.
The cornerstone of therapy is -blocker treatment. In addition, lifestyle advice should be an integral part of therapy; in particular, the avoidance of strenuous exercise (eg, competitive sports). An ICD might be occasionally needed, but the -blocker therapy should not be discontinued.
Other Inherited Arrhythmia Disorders
There are a few other arrhythmia syndromes that segregate as an autosomal dominant trait, including atrial fibrillation, sinus node dysfunction and/or atrial standstill. Ion channel genes seem to be involved with or without modifier genes. For atrial fibrillation the number of genes is rapidly increasing. At present, at least 4 genes have been shown to be causal, together with 3 loci with unknown genes ( Table 1 ). Several of the identified genes encode for potassium-channel subunits (Table 1) . Interestingly, somatic mutations in the gene encoding for connexin 40, the main atrial connexin and an important player in atrial conduction, have been recently detected in cardiac tissue of lone atrial fibrillation patients. 55 The familial forms seem rather rare. Familial sinus node dysfunction is, not surprisingly, caused by a dysfunction of the pacemaker channel, but SCN5a may also be involved when present as compound heterozygous mutations (Table 1) . Finally, isolated conduction disease has been linked to mutations in SCN5a and a number of other, as yet unknown, genes (Table 1) . 56 
Genetic Testing in Inherited Arrhythmia Disorders
As discussed earlier the identification of causal genes for inherited arrhythmia syndromes has enabled the possibility of identifying asymptomatic carriers. This process, referred to as presymptomatic counseling, has been the subject of a lot of debate, in particular when it includes children, as will be the case for several of the primary arrhythmia syndromes (for review see van Langen et al 57 ). There is a lack of relevant experience in the field of cardiogenetics, whereas geneticists and associated professionals do have experience with presymptomatic testing in neurological diseases and malignancies (neurogenetics and oncogenetics, respectively). 57 The few studies performed in LQTS patients reveal significant psychosocial disturbances, in particular in parents of affected children. 58, 59 Before genetic testing becomes widely available in routine clinical practiceg much more research in this field is needed.
The yield of molecular genetic testing varies between different diseases. It seems highest in LQTS, with a worldwide (mean) yield of 60-70%. [60] [61] [62] With a proven familial nature (ie, more than 1 family member clinically affected and/or with a young (≤40 years) deceased family member) the yield is significantly higher. 62 Also, usage of the genespecific features increases the yield. 63 In BS the percentage is considerably lower, with a value somewhere between 20% and 30% SCN5a involvement. 62 The impact of the recent identification of new genes in the latter disease entity remains to be established. For the other inherited arrhythmia syndromes no reliable numbers are available.
Summary
In recent years the molecular basis of many inherited arrhythmia syndromes has been unraveled and to date new causal genes are identified. The number of truly idiopathic arrhythmias is decreasing with every gene identified. Although small, the proportion of arrhythmias that are hereditary is not insignificant. In particular, these diseases underlie a substantial number of cases of premature sudden death, and identification of the causal genes allows for timely and tailored treatment of eventually affected family members (gene carriers). This development has also markedly increased the basic knowledge of ion channel physiology and pathophysiology and it is likely that many more patients (suffering from more common arrhythmia syndromes) will benefit from this development in future years.
